E7449
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for E7449, covering 2015-08-25 to 2023-06-18. Get the full timeline:
Most recent: Clinical Trial Update: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]